Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Ripretinib Shows Preliminary Activity and Safety in Advanced Sarcoma

August 21st 2020

Ripretinib demonstrated promising antitumor activity and was found to be well tolerated in patients with refractory advanced gastrointestinal stromal tumor.

Dr. Somaiah on Remaining Challenges in Soft Tissue Sarcoma

August 20th 2020

Neeta Somaiah, MD, discusses remaining challenges in soft tissue sarcoma.

Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma

August 19th 2020

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

SM-88 Moves Forward in HopES Sarcoma Trial

August 17th 2020

The interim futility review for the phase 2 HopES Sarcoma trial was positive and will continue to evaluate SM-88 for patients with Ewing sarcoma and other high-risk sarcomas.

Dr. Abraham on Key Considerations in the Management of TGCT

August 11th 2020

John A. Abraham, MD, FACS, discusses key considerations regarding the management of tenosynovial giant cell tumor.

FDA Grants Pedmark Priority Review for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

August 7th 2020

The FDA has granted a priority review designation to a new drug application for a unique formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.

Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma

August 7th 2020

Jonathan C. Trent, MD, PhD, discusses the role of circulating tumor DNA in soft tissue sarcoma.

Dr. Schwartz on Results From the GIST Cohort in the Alliance A091401 Trial

August 6th 2020

Gary K. Schwartz, MD, discusses the results from the gastrointestinal stromal tumor cohort of the phase 2 Alliance A091401 trial.

Dr. Roland on the Safety of Neoadjuvant Checkpoint Blockade in Sarcoma

August 5th 2020

Christina L. Roland, MD, MS, FACS, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Dr. Schwartz on the Updated Design of the Alliance A091401 Trial in Metastatic Sarcomas

July 31st 2020

Gary K. Schwartz, MD, discusses the updated design of the phase 2 Alliance A091401 trial for metastatic sarcomas.

Dr. Schwartz on Future Research in Sarcoma

July 30th 2020

Gary K. Schwartz, MD, discusses future research in sarcoma.

Dr. Roland on the Rationale for a Neoadjuvant Checkpoint Blockade in Sarcoma

July 30th 2020

Christina L. Roland, MD, PhD, discusses the rationale for a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

July 29th 2020

R. Lor Randall, MD, FACS, discusses preoperative radiotherapy and how it has become a standard of care for patients with soft tissue sarcoma of the extremities; however, postoperative radiation still plays a role in the paradigm, especially when wound risks are considered to be precarious.

Dr. Roland on Neoadjuvant Checkpoint Blockade in Sarcoma Subtypes

July 28th 2020

Christina L. Roland, MD, PhD, discusses the design of a randomized, phase 2 trial with nivolumab and ipilimumab in resectable retroperitoneal dedifferentiated liposarcoma, as well as radiation therapy in extremity/truncal undifferentiated pleomorphic sarcoma.

Nivolumab/Ipilimumab Shows Intriguing Clinical Activity in Metastatic Sarcomas

July 28th 2020

Gary K. Schwartz, MD, discusses the clinical findings with the combination of nivolumab and ipilimumab in patients with dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

European Medicines Agency Grants PRIME Access to ADP-A2M4 for Synovial Sarcoma

July 27th 2020

The European Medicines Agency has granted access to the PRIME initiative for the Specific Peptide Enhanced Affinity Receptor T-cell therapy ADP-A2M4 for the treatment of patients with synovial sarcoma.

Dr. Gronchi on the Rationale for the TRASTS Study in Soft Tissue Sarcoma

July 23rd 2020

Alessandro Gronchi, MD, discusses the rationale for the phase 2 TRASTS study in soft tissue sarcoma.

Ripretinib Takes Step Toward Chinese Approval for Advanced GIST

July 21st 2020

The China National Medical Products Administration has accepted a new drug application for ripretinib as a treatment for adult patients with advanced gastrointestinal stromal tumor who have received previous treatment with 3 or more kinase inhibitors, including imatinib.

NCCN Publishes Guidelines Listing Pexidartinib as Category 1 Recommended Therapy in TGCT

July 20th 2020

The National Comprehensive Cancer Network recently published updated Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma, listing pexidartinib as a systemic treatment for patients with tenosynovial giant cell tumor.

Dr. Schwartz on the Results of the Alliance A091401 Study in Metastatic Sarcoma

July 1st 2020

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.